Stay updated with breaking news from Baxter Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Global Biopharmaceutical Contract Manufacturing Industry, valued at approximately US$ 9.3 billion in 2022, is set to experience robust growth at a Compound Annual Growth Rate (CAGR) of 10.5%. It is expected to reach a staggering US$ 18.7 billion by 2029. This meteoric rise reflects the growing trend among pharma...
Global Biopharmaceutical Contract Manufacturing Market was estimated to be worth roughly US$ 9.3 Billion in 2022 and is expected to grow at a CAGR of 10.5% to reach US$ 18.7 billion by 2029.A few benefits provided by biopharmaceutical manufacturing businesses include access to pricey technologies, a shorter overall...
Global Biopharmaceutical Contract Manufacturing Market was estimated to be worth roughly US$ 8.4 billion in 2021 and is expected to grow at a CAGR of 10.5% to reach US$ 18.7 billion by 2029.A few benefits provided by biopharmaceutical manufacturing businesses include access to pricey technologies, a shorter overall...
Reduced overall time to market investment in new drugs, access to expensive technologies, and greater flexibility are some advantages offered by biopharmaceutical manufacturing companies. On the back of these factors, several large companies have outsourced their biopharmaceutical manufacturing operations. Biopharma...
Global biopharmaceutical contract manufacturing market was estimated to be worth roughly US$ 8.4 billion in 2021 and is expected to grow at a CAGR of 10.5% to reach US$ 18.7 billion by 2029.Reduced overall time to market investment in new drugs, access to expensive technologies, and greater flexibility are some adva...